What Mounjaro means — the name, the drug, and how it actually works

Step 1: where the name comes from (and why it doesn't tell you much)

Pharmaceutical companies invent brand names for commercial and regulatory reasons, they are easier to trademark and distinguish from the generic drug name. Mounjaro is Eli Lilly's chosen brand for tirzepatide; the word does not come from Latin, Greek or any clinical vocabulary. A question our prescribers hear most weeks is whether the name signals something about the drug's strength or its target, it doesn't. The name to learn is tirzepatide, because that is the active ingredient, the word that appears in clinical guidance, and the term used by the NICE appraisal of tirzepatide (TA1026) that shaped NHS access to this treatment. If you are curious about where the word Mounjaro originates and what it is understood to mean, our dedicated page picks that apart further. For the purposes of your health, though, the mechanism matters far more than the name.

Tirzepatide is made as a KwikPen, a pre-filled device containing four weekly doses. You inject it once a week under the skin of your abdomen, thigh or upper arm, rotating sites each time. The pen itself is discreet, engineered to make self-injection straightforward even for people who have never used an injectable medicine before.

Step 2: how tirzepatide works in the body

Most weight-loss injections currently available target a single gut hormone called GLP-1 (glucagon-like peptide-1). Tirzepatide does something different: it also activates GIP (glucose-dependent insulinotropic polypeptide). Both are hormones released after eating, and both influence appetite, blood sugar and how quickly the stomach empties. By stimulating both receptors simultaneously, tirzepatide produces a stronger reduction in hunger signals than a single-pathway drug alone, which is why researchers describe it as a dual agonist.

In practical terms, most people notice they feel full sooner during meals and less interested in food between them. Gastric emptying slows, which spreads glucose absorption and softens blood-sugar spikes. The NHS medicines page for tirzepatide explains the pharmacology in plain language and lists the side effects you should know before starting.

The most common side effects are gastrointestinal: nausea, loose stools, constipation, indigestion and burping appear most often in the early weeks or after a dose increase, and they usually ease as the body adjusts. Fatigue and dizziness are also reported. Rare but serious reactions (including acute pancreatitis) require prompt medical attention; the MHRA issued a Drug Safety Update on this in January 2026, and any severe stomach pain that spreads to the back should be assessed the same day.

Step 3: what the clinical evidence actually found

The SURMOUNT-1 trial randomised 2,539 adults with obesity to tirzepatide or placebo over 72 weeks. At the 15 mg dose, average body-weight reduction was around 20–21%. That figure comes from a controlled trial with strict lifestyle support alongside the medicine, results in everyday use vary. Head-to-head data from SURMOUNT-5 (published in the New England Journal of Medicine, 2025) showed tirzepatide produced greater average weight loss than semaglutide 2.4 mg over the same period, making it the strongest evidence base we have for comparing the two injections. If you are weighing the two options, our overview of tirzepatide covers the comparison in detail, and our Mounjaro treatment page explains the prescription process.

These trial results are why NICE recommended tirzepatide in December 2024 for adults with a BMI of 35 or above and at least one weight-related condition, and why private prescribers can offer it to a wider group under the licensed eligibility criteria, which include a BMI of 30 or above, or 27 with a qualifying condition.

Step 4: getting a prescription and what to expect

Mounjaro is a prescription-only medicine, which means it cannot legally be supplied without a prescriber's assessment. That applies whether you go through the NHS or a private pharmacy. The NHS route is available to a defined and currently limited group; for many people, a regulated private service is the realistic option. Our page on Mounjaro pricing in the UK explains honestly what private treatment typically costs and what you should expect that price to include. For longer-term questions about whether this is a medicine you might stay on, this page on long-term use covers what the evidence and clinical guidance currently say.

At nume, a GPhC-registered Independent Prescriber reviews every consultation personally on the day it is submitted. There are no algorithms making the clinical call. If treatment is approved, the pen is dispatched the same day for free next-working-day delivery by DPD, in plain packaging. Our clinical team is available for aftercare seven days a week. If you have questions before starting, our FAQs cover the practicalities most people ask about first.

Speak to our prescribers through a free consultation (no referral, no waiting list) and find out whether Mounjaro is clinically suitable for you via our treatment page.